Pharmaceuticals & Biotech/Lifesciences

FNArena Windows (Sectors)

Introduction to FNArena Windows

FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.

Latest Stories

Brokers remain generally upbeat on CSL and focus upon the earnings contribution from the Vifor Pharma acquisition 

Sep 30 2022

Tim Boreham digs deep into the evolving world of cancer diagnostics, highlighting the newly named Inoviq Ltd

Sep 19 2022


ASX CODE COMPANY NAME LAST PRICE 52WK HIGH 52WK LOW P/E CONSENSUS TARGET
ANP ANTISENSE THERAPEUTICS LIMITED $0.08 $0.35 $0.07

$0.26

CSL CSL LIMITED $286.74 $319.78 $0.00 36.7

$324.80

MDC MEDLAB CLINICAL LIMITED $11.04 $30.00 $0.00

$44.53

MYX MAYNE PHARMA GROUP LIMITED $0.28 $0.43 $0.20

$0.335

PAR PARADIGM BIOPHARMACEUTICALS LIMITED $1.26 $2.69 $0.86

$0.79

PNV POLYNOVO LIMITED $1.40 $xx.xx $xx.xx xx.x xx.xx
PXS POLYNOVO LIMITED $0.08 $xx.xx $xx.xx xx.x xx.xx
TRP TISSUE REPAIR LIMITED $0.30 $xx.xx $xx.xx xx.x xx.xx
Previous Stories
CSL: Offering Buying Opportunity

Sep 13 2022

Michael Gable of Fairmont Equities notes price action suggests CSL is a buying opportunity, and more so on a breakout


Dr Boreham’s Crucible: Vaxxas Pty Ltd

Sep 07 2022

Vaxxas is still unlisted, but worth highlighting as yet another Australian success story looks to be unfolding, reports Tim Boreham


Dr Boreham’s Crucible: Telix Pharmaceuticals

Aug 22 2022

Telix Pharmaceuticals’ prostate cancer imaging product Illucix is quickly conquering the USA, but management at the firm has (much) higher ambitions


Dr Boreham’s Crucible: Orthocell

Jul 26 2022

Micro-cap biotech Orthocell is aiming to emulate the successful growth story of Polynovo, nowadays capitalised at $1.1bn


CSL: Buy Trigger Ahead

Apr 26 2022

Michael Gable of Fairmont Equities notes that after two years in the lockdown doldrums, CSL is getting ready to break out


Why CSL Fell Sharply Yesterday

Dec 17 2021

FNArena has received a number of enquiries as to why the big CSL share price fall yesterday. For the less experienced, here is the explanation


Beating The Biotech Blues

Sep 14 2021

Janus Henderson’s Andy Acker explains why small and mid-cap biotechs have seriously underperformed, and why a strong recovery could be expected


Uncertainty Prevails For CSL

Aug 19 2021

Timing will be everything for CSL, which is endeavouring to keep up the flow of plasma while collections activity remains beset by the pandemic


Flying High – Medicinal Marijuana In Australia

Jul 26 2021

Australia has the potential to become the international gold standard for production of medicinal marijuana and multiple ASX-listed companies are seeking to benefit


Wesfarmers On Drugs?

Jul 13 2021

Wesfarmers has flagged its planned expansion into the personal care, health and well-being sector with a bid for Australian Pharmaceutical Industries that has surprised brokers